Enhanced Preproenkephalin-B-Derived Opioid Transmission in Striatum and Subthalamic Nucleus Converges Upon Globus Pallidus Internalis in L-3,4-dihydroxyphenylalanine-Induced Dyskinesia

Biological Psychiatry

Volumn 61, Issue 7, 2007, Pages 836-844

  Aubert, Incarnation ^a   Guigoni, Céline ^b   Li, Qin ^c   Dovero, Sandra ^b   Bioulac, Bernard H ^b   Gross, Christian E ^b   Crossman, Alan R ^d   Bloch, Bertrand ^a   Bezard, Erwan ^b  

^a Centre National   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CHINA AGRICULTURAL UNIVERSITY   (China)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Dyskinesia; globus pallidus pars internalis; neuropeptide; striatum; subthalamic nucleus; ; opioid receptors;

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; LEVODOPA; MESSENGER RNA; MU OPIATE RECEPTOR; OPIATE; PREPROENKEPHALIN; PREPROENKEPHALIN A; PRODYNORPHIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; MACACA; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SUBTHALAMIC NUCLEUS;

EID: 33947252825     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.06.038     Document Type: Article

References (58)

1. Alexander G.E., and Crutcher M.D. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 13 (1990) 266-271
2. Aubert I., Ghorayeb I., Normand E., and Bloch B. Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum. J Comp Neurol 418 (2000) 22-32
3. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D(1) dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
4. Baik J.H., Picetti R., Saiardi A., Thiriet G., Dierich A., Depaulis A., et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377 (1995) 424-428
5. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., and Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18 (1998) 5301-5310
6. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci 2 (2001) 577-588
7. Bezard E., Dovero S., Belin D., Duconger S., Jackson-Lewis V., Przedborski S., et al. Enriched environment confers resistance to MPTP and cocaine: Involvement of dopamine transporter and neurotrophic factors. J Neurosci 23 (2003) 10999-11007
8. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. J Neurosci 21 (2001) 6853-6861
9. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9 (2003) 762-767
10. Bezard E., Gross C.E., Qin L., Gurevich V.V., Benovic J.L., and Gurevichc E.V. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis 18 (2005) 323-335
11. Boraud T., Bezard E., Bioulac B., and Gross C. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alteration of pallidal neurons in the MPTP-treated monkey. Brain 124 (2001) 546-557
12. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di P.T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61 (2002) 186-196
13. Cenci M.A. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 23 (2002) 105-109
14. Cenci M.A., Lee C.S., and Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10 (1998) 2694-2706
15. Duty S., Henry B., Crossman A.R., and Brotchie J.M. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp Neurol 150 (1998) 223-234
16. Engber T.M., Boldry R.C., Kuo S., and Chase T.N. Dopaminergic modulation of striatal neuropeptides: Differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 581 (1992) 261-268
17. Fernandez A., de Ceballos M.L., Jenner P., and Marsden C.D. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience 61 (1994) 73-79
18. Fox S., Silverdale M., Kellett M., Davies R., Steiger M., Fletcher N., et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov Disord 19 (2004) 554-560
19. Gerfen C.R. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23 (2000) S64-S70
20. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
21. Gerfen C.R., McGinty J.F., and Young III W.S. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: In situ hybridization histochemical analysis. J Neurosci 11 (1991) 1016-1031
22. Guigoni C., Dovero S., Aubert I., Li Q., Bioulac B.H., Bloch B., et al. Levodopa-induced dyskinesia in MPTP-treated macaque is not dependent of the extent and pattern of the nigrostrial lesion. Eur J Neurosci 22 (2005) 283-287
23. Guigoni C., Qin L., Aubert I., Dovero S., Bioulac B.H., Bloch B., et al. Involvement of sensorimotor, limbic, and association basal ganglia domains in levodopa-induced dyskinesia. J Neurosci 28 (2005) 2102-2107
24. Henry B., Crossman A.R., and Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155 (1999) 204-220
25. Henry B., Duty S., Fox S.H., Crossman A.R., and Brotchie J.M. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 183 (2003) 458-468
26. Henry B., Fox S.H., Crossman A.R., and Brotchie J.M. mu- and delta-Opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's Disease. Exp Neurol 171 (2001) 139-146
27. Herrero M.T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin M.R., Agid Y., et al. Effects of L-Dopa on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68 (1995) 1189-1198
28. Hollt V. Opioid peptide processing and receptor selectivity. Annu Rev Pharmacol Toxicol 26 (1986) 59-77
29. Hoover B.R., and Marshall J.F. Further characterization of preproenkephalin mRNA-containing cells in the rodent globus pallidus. Neuroscience 111 (2002) 111-125
30. Horikawa S., Takai T., Toyosato M., Takahashi H., Noda M., Kakidani H., et al. Isolation and structural organization of the human preproenkephalin B gene. Nature 306 (1983) 611-614
31. Hutchinson W.D., Levy R., Dostrovsky J.O., Lozano A.M., and Lang A.E. Effects of apomorphine on Globus Pallidus neurons in parkinsonian patients. Ann Neurol 42 (1997) 767-775
32. Johansson P.A., Andersson M., Andersson K.E., and Cenci M.A. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-dopa-induced dyskinesia. Neurobiol Dis 8 (2001) 220-239
33. Law P.Y., Wong Y.H., and Loh H.H. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40 (2000) 389-430
34. Le Moine C., Bernard V., and Bloch B. Quantitative in situ hybridization using radioactive probes in the study of gene expression in heterocellular systems. Methods Mol Biol 33 (1994) 301-311
35. Mansour A., Fox C.A., Burke S., Meng F., Thompson R.C., Akil H., and Watson S.J. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 350 (1994) 412-438
36. Mansour A., Hoversten M.T., Taylor L.P., Watson S.J., and Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: Evidence for two opioid peptide recognition cores. Brain Res 700 (1995) 89-98
37. Marie N., Lecoq I., Jauzac P., and Allouche S. Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists. J Biol Chem 278 (2003) 22795-22804
38. Merchenthaler I., Maderdrut J.L., Cianchetta P., Shughrue P., and Bronstein D. In situ hybridization histochemical localization of prodynorphin messenger RNA in the central nervous system of the rat. J Comp Neurol 384 (1997) 211-232
39. 2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-Dopa therapy. Mol Brain Res 49 (1997) 55-62
40. Morissette M., Grondin R., Goulet M., Bedard P.J., and Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D-1 or D-2 receptor agonists. J Neurochem 72 (1999) 682-692
41. Nambu A., Tokuno H., and Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res 43 (2002) 111-117
42. Nisbet A.P., Foster O.J.F., Kingsbury A.E., Eve D.J., Daniel S.E., Marsden C.D., and Lees A.J. Preproenkephalin and preprotatachykinin messenger RNA expression in normal basal ganglia and in Parkinson's disease. Neuroscience 66 (1995) 361-376
43. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., and Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model. Ann Neurol 47 (2000) S22-S32
44. Papa S.M., Desimone R., Fiorani M., and Oldfield E.H. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 46 (1999) 732-738
45. Piccini P., Weeks R.A., and Brooks D.J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 42 (1997) 720-726
46. Rascol O., Fabre N., Blin O., Poulik J., Sabatini U., Senard J.M., et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 9 (1994) 437-440
47. Sadee W., Wang D., and Bilsky E.J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci 76 (2005) 1427-1437
48. Samadi P., Gregoire L., and Bedard P.J. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: Interaction between dopamine and opioid systems. Neuropharmacology 45 (2003) 954-963
49. Schulz R., Wuster M., and Herz A. Endogenous ligands for kappa-opiate receptors. Peptides 3 (1982) 973-976
50. Simonds W.F. The molecular basis of opioid receptor function. Endocr Rev 9 (1988) 200-212
51. Smith J.A., Leslie F.M., Broide R.S., and Loughlin S.E. Long-term changes in striatal opioid systems after 6-hydroxydopamine lesion of rat substantia nigra. Neuroscience 55 (1993) 935-951
52. Sprenger T., Berthele A., Platzer S., Boecker H., and Tolle T.R. What to learn from in vivo opioidergic brain imaging?. Eur J Pain 9 (2005) 117-121
53. Tel B.C., Zeng B.Y., Cannizzaro C., Pearce R.K., Rose S., and Jenner P. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115 (2002) 1047-1058
54. Westin J.E., Andersson M., Lundblad M., and Cenci M.A. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14 (2001) 1171-1176
55. Winkler C., Kirik D., Bjorklund A., and Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10 (2002) 165-186
56. Yahr M.D., Duvoisin R.C., Hoehn M.M., Schear M.J., and Barrett R.E. L-Dopa: Its clinical effects in parkinsonism. Trans Amer Neurol Ass 93 (1968) 56-63
57. Yoshikawa K., Williams C., and Sabol S.L. Rat brain preproenkephalin mRNA. cDNA cloning, primary structure, and distribution in the central nervous system. J Biol Chem 259 (1984) 14301-14308
58. Zeng B.Y., Pearce R.K.B., MacKenzie G.M., and Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12 (2000) 1096-1104